These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22946947)

  • 41. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials.
    Chen YF; Wang SJ; Khin NA; Hung HM; Laughren TP
    Pharm Stat; 2010; 9(3):217-29. PubMed ID: 20872622
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mixed noninferiority margin and statistical tests in active controlled trials.
    Tsou HH; Hsiao CF; Chow SC; Yue L; Xu Y; Lee S
    J Biopharm Stat; 2007; 17(2):339-57. PubMed ID: 17365228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regional differences in multinational clinical trials: anticipating chance variation.
    Marschner IC
    Clin Trials; 2010 Apr; 7(2):147-56. PubMed ID: 20338904
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population enrichment designs: case study of a large multinational trial.
    Mehta CR; Gao P
    J Biopharm Stat; 2011 Jul; 21(4):831-45. PubMed ID: 21516572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sample size determination for a specific region in multiregional clinical trials with multiple co-primary endpoints.
    Huang WS; Hung HN; Hamasaki T; Hsiao CF
    PLoS One; 2017; 12(6):e0180405. PubMed ID: 28665972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.
    Diao G; Zeng D; Ibrahim JG; Rong A; Lee O; Zhang K; Chen Q
    J Biopharm Stat; 2017; 27(6):933-944. PubMed ID: 28296570
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multi-regional clinical trial design and consistency assessment of treatment effects.
    Quan H; Mao X; Chen J; Shih WJ; Ouyang SP; Zhang J; Zhao PL; Binkowitz B
    Stat Med; 2014 Jun; 33(13):2191-205. PubMed ID: 24515845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sample size estimation: an overview with applications to orthodontic clinical trial designs.
    Pandis N; Polychronopoulou A; Eliades T
    Am J Orthod Dentofacial Orthop; 2011 Oct; 140(4):e141-6. PubMed ID: 21967951
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Self-designing trial combined with classical group sequential monitoring.
    Yin G; Shen Y
    J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sample size and the probability of a successful trial.
    Chuang-Stein C
    Pharm Stat; 2006; 5(4):305-9. PubMed ID: 17128428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Practical issues and lessons learned from multi-regional clinical trials via case examples: a Japanese perspective.
    Ando Y; Hamasaki T
    Pharm Stat; 2010; 9(3):190-200. PubMed ID: 20737442
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [What to do if statistical power is low? A practical strategy for pre-post-designs].
    Müller J; Manz R; Hoyer J
    Psychother Psychosom Med Psychol; 2002; 52(9-10):408-16. PubMed ID: 12355348
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sample size and proportion of Japanese patients in multi-regional trials.
    Ikeda K; Bretz F
    Pharm Stat; 2010; 9(3):207-16. PubMed ID: 20872621
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of interval estimations in design and evaluation of multiregional clinical trials with continuous outcomes.
    Chiang C; Hsiao CF
    Stat Methods Med Res; 2019 Jul; 28(7):2179-2195. PubMed ID: 29355082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of two ethnic populations using distribution adjusted mean.
    Cai Z; Uesaka H; Tsujimoto M
    J Biopharm Stat; 2013 May; 23(3):539-58. PubMed ID: 23611194
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test.
    Brookes ST; Whitely E; Egger M; Smith GD; Mulheran PA; Peters TJ
    J Clin Epidemiol; 2004 Mar; 57(3):229-36. PubMed ID: 15066682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessing consistent treatment effect in a multi-regional clinical trial: a systematic review.
    Chen J; Quan H; Binkowitz B; Ouyang SP; Tanaka Y; Li G; Menjoge S; Ibia E;
    Pharm Stat; 2010; 9(3):242-53. PubMed ID: 20872623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.